Chipscreen Out-licenses Taiwanese Rights for Cancer Drug to GNT Biotech

Shenzhen Chipscreen Biosciences has out-licensed Taiwanese rights for a cancer drug candidate, Chidamide, to GNT Biotech and Medicals of Taiwan. Chidamide is an oral, selective histone deacetylase (HDAC) inhibitor that is currently being tested in a China Phase II clinical trial. Financial details of the agreement were not disclosed. More details.... Share this with colleagues: // //